Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway

DIRICAN, A.; Atmaca, H.; Bozkurt, E.; ERTEN, C.; KARACA, BETÜL; Uslu, RÜÇHAN

doi:10.1007/s12094-014-1206-6

Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway

Atıf İçin Kopyala

DIRICAN A., Atmaca H., Bozkurt E., ERTEN C., KARACA B., Uslu R.

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.17, ss.145-151, 2015 (SCI İndekslerine Giren Dergi)

Cilt numarası: 17 Konu: 2
Basım Tarihi: 2015
Doi Numarası: 10.1007/s12094-014-1206-6
Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
Sayfa Sayıları: ss.145-151

Özet

The treatment of castrate-resistant prostate cancer (CRPC) still remains as an important challenge of daily oncology practice. Docetaxel significantly prolongs overall survival in men with CRPC. Thymoquinone (TQ), one of the flavonoid compounds isolated from Nigealla sativa, has been shown to possess cytotoxic activity against a variety of cancer cell lines.